Arnaud Foussat

Operating Partner - Advent France Biotechnology

Dr. Arnaud Foussat is Operating Partner at Advent France Biotechnology.
Before joining Advent France Biotechnology, Arnaud was Chief Scientific Officer at TxCell (acquired by Sangamo Therapeutics in 2018) and developed the first generation of cell therapy products using Regulatory T cells (Treg cells) and launched the first program on CAR-engineered Treg cells. Arnaud spent 12 years at TxCell, managing the cell therapy research and process development with a strong involvement in regulatory affairs and corporate development. Graduate of Institut Pasteur of Paris, Arnaud Foussat obtained his Ph.D. degree of Immunology from the University of Paris VII in 2000. He then joined a French academic laboratory belonging to the French National Institute of Scientific and Medical Research (INSERM) where he focused his scientific efforts on the elucidation of the migratory pathways of Treg cells in normal and pathological conditions. Arnaud is also CEO of Alderaan Biotechnology and Yukin therapeutics, two companies from Advent France Biotechnology’s portfolio.